Bioavailability of bioactive food compounds: a challenging journey to bioefficacy
- PMID: 22897361
- PMCID: PMC3575927
- DOI: 10.1111/j.1365-2125.2012.04425.x
Bioavailability of bioactive food compounds: a challenging journey to bioefficacy
Abstract
Bioavailability is a key step in ensuring bioefficacy of bioactive food compounds or oral drugs. Bioavailability is a complex process involving several different stages: liberation, absorption, distribution, metabolism and elimination phases (LADME). Bioactive food compounds, whether derived from various plant or animal sources, need to be bioavailable in order to exert any beneficial effects. Through a better understanding of the digestive fate of bioactive food compounds we can impact the promotion of health and improvement of performance. Many varying factors affect bioavailability, such as bioaccessibility, food matrix effect, transporters, molecular structures and metabolizing enzymes. Bioefficacy may be improved through enhanced bioavailability. Therefore, several technologies have been developed to improve the bioavailability of xenobiotics, including structural modifications, nanotechnology and colloidal systems. Due to the complex nature of food bioactive compounds and also to the different mechanisms of absorption of hydrophilic and lipophilic bioactive compounds, unravelling the bioavailability of food constituents is challenging. Among the food sources discussed during this review, coffee, tea, citrus fruit and fish oil were included as sources of food bioactive compounds (e.g. (poly)phenols and polyunsaturated fatty acids (PUFAs)) since they are examples of important ingredients for the food industry. Although there are many studies reporting on bioavailability and bioefficacy of these bioactive food components, understanding their interactions, metabolism and mechanism of action still requires extensive work. This review focuses on some of the major factors affecting the bioavailability of the aforementioned bioactive food compounds.
© 2012 Nestec S. A.. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.
Figures
, drug;
, polyphenols;
, other food ingredients;
, micelles;
, PUFAs in form of TAG;
, Metabolites (from drugs and polyphenols);
, microbial metabolites;
, phase I and phase II metabolites;
, PUFA hydrolyzed from TAG;
, PUFA re‐esterified as TAG and released as chylomicronReferences
-
- Kussmann M, Affolter M, Nagy K, Holst B, Fay LB. Mass spectrometry in nutrition: understanding dietary health effects at the molecular level. Mass Spectrom Rev. 2007;26:727–750. - PubMed
-
- Espìn JC, Garcìa‐Conesa MT, Tomàs‐Barberàn FA. Nutraceuticals: facts and fiction. Phytochemistry. 2007;68:2986–3008. - PubMed
-
- Arts IC, Hollman PC. Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr. 2005;81(1 Suppl.):317S–325. - PubMed
-
- Joshipura KJ, Ascherio A, Manson JE, Stampfer MJ, Rimm EB, Speizer FE, Hennekens CH, Spiegelman D, Willett WC. Fruit and vegetable intake in relation to risk of ischemic stroke. JAMA. 1999;282:1233–1239. - PubMed
-
- Patil BS, Jayaprakasha GK, Chidambara Murthy KN, Vikram A. Bioactive compounds: historical perspectives, opportunities, and challenges. J Agric Food Chem. 2009;57:8142–8160. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
